20 M.M.G. Pimentel et al. / Neuroscience Letters 433 (2008) 17–21
Acknowledgments
We thank the patients, their families and healthy volunteers.
We also thank Dr. Vincenzo Bonifati for helpful communica-
tion concerning the PCR procedures and D
´
ebora Torres Valenc¸a
for technical assistance. We are also grateful to the “Plataforma
Gen
ˆ
omica - Sequenciamento de DNA/PDTIS-FIOCRUZ” for
the aid with the automatic sequencing system. This study
was supported by grants from PPSUS-MS/CNPq/FAPERJ (E-
26/171.560/2006), CAPES and CEPUERJ.
References
[1] P.M. Abou-Sleiman, M.M. Muqit, N.W. Wood, Expanding insights of mito-
chondrial dysfunction in Parkinson’s disease, Nat. Rev. Neurosci. 7 (2006)
207–219.
[2] V. Bonifati, LRRK2 low-penetrance mutations (Gly2019Ser) and risk alle-
les (Gly2385Arg)—Linking familial and sporadic Parkinson’s disease,
Neurochem. Res. 32 (2007) 1700–1708.
[3] V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, E. Krieger,
M.C.J. Dekker, F. Squitieri, P. Ibanez, M. Joosse, J.W. van Dongen, N.
Vanacore, J.C. van Swieten, A. Brice, G. Meco, C.M. van Duijn, B.A.
Oostra, P. Heutink, Mutations in the DJ-1 gene associated with autosomal
recessive early-onset parkinsonism, Science 299 (2003) 256–259.
[4] J.M. Bras, R.J. Guerreiro, M.H. Ribeiro, C. Januario, A. Morgadinho, C.R.
Oliveira, L. Cunha, J. Hardy, A. Singleton, G2019S dardarin substitution
is a common cause of Parkinson’s disease in a Portuguese cohort, Mov.
Disord. 20 (2005) 1653–1655.
[5] L.N. Clark, Y. Wang, E. Karlins, L. Saito, H. Mejia-Santana, J. Harris, E.D.
Louis, L.J. Cote, H. Andrews, S. Fahn, C. Waters, B. Ford, S. Frucht, R.
Ottman, K. Marder, Frequency of LRRK2 mutations in early- and late-onset
Parkinson disease, Neurology 67 (2006) 1786–1791.
[6] A. Di Fonzo, C.F. Rohe, J. Ferreira, H.F. Chien, L. Vacca, F. Stocchi, L.
Guedes, E. Fabrizio, M. Manfredi, N. Vanacore, S. Goldwurm, G. Breed-
veld, C. Sampaio, G. Meco, E. Barbosa, B.A. Oostra, V. Bonifati, Italian
Parkinson genetics network, a frequent LRRK2 gene mutation associated
with autosomal dominant Parkinson’s disease, Lancet 365 (2005) 410–
412.
[7] A. Di Fonzo, C. Tassorelli, M. De Mari, H.F. Chien, J. Ferreira, C.F.
Rohe, G. Riboldazzi, A. Antonini, G. Albani, A. Mauro, R. Marconi, G.
Abbruzzese, L. Lopiano, E. Fincati, M. Guidi, P. Marini, F. Stocchi, M.
Onofrj, V. Toni, M. Tinazzi, G. Fabbrini, P. Lamberti, N. Vanacore, G.
Meco, P. Leitner, R.J. Uitti, Z.K. Wszolek, T. Gasser, E.J. Simons, G.J.
Breedveld, S. Goldwurm, G. Pezzoli, C. Sampaio, E. Barbosa, E. Mar-
tignoni, B.A. Oostra, V. Bonifati, Italian Parkinson’s genetics network,
comprehensive analysis of the LRRK2 gene in sixty families with Parkin-
son’s disease, Eur. J. Hum. Genet. 14 (2006) 322–331.
[8] E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Hol-
loway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf,
C.M. Tanner, Projected number of people with Parkinson disease in the
most populous nations, 2005 through 2030, Neurology 68 (2007) 384–386.
[9] M.J. Farrer, Genetics of Parkinson disease: paradigm shifts and future
prospects, Nat. Rev. Genet. 7 (2006) 306–318.
[10] J.J. Ferreira, L.C. Guedes, M.M. Rosa, M. Coelho, M. van Doeselaar, D.
Schweiger, A. Di Fonzo, B.A. Oostra, C. Sampaio, V. Bonifati, High preva-
lence of LRRK2 mutations in familial and sporadic Parkinson’s disease in
Portugal, Mov. Disord. 22 (2007) 1194–1201.
[11] T. Foroud, LRRK2: both a cause and a risk factor for Parkinson disease?
Neurology 65 (2005) 664–665.
[12] W.P. Gilks, P.M. Abou-Sleiman, S. Gandhi, S. Jain, A. Singleton, A.J. Lees,
K. Shaw, K.P. Bhatia, V. Bonifati, N.P. Quinn, J. Lynch, D.G. Healy, J.L.
Holton, T. Revesz, N.W. Wood, A common LRRK2 mutation in idopathic
Parkinson’s disease, Lancet 365 (2005) 415–416.
[13] C.J. Gloeckner, N. Kinkl, A. Schumacher, R.J. Braun, E. O’Neill, T.
Meitinger, W. Kolch, H. Prokisch, M. Ueffing, The Parkinson disease caus-
ing LRRK2 mutation I2020T is associated with increased kinase activity,
Hum. Mol. Genet. 15 (2006) 223–232.
[14] S. Goldwurm, A. Di Fonzo, E.J. Simons, C.F. Rohe, M. Zini, M. Canesi,
S. Tesei, A. Zecchinelli, A. Antonini, C. Mariani, N. Meucci, G. Sacilotto,
F. Sironi, G. Salani, J. Ferreira, H.F. Chien, E. Fabrizio, N. Vanacore, A.
Dalla Libera, F. Stocchi, C. Diroma, P. Lamberti, C. Sampaio, G. Meco, E.
Barbosa, A.M. Bertoli-Avella, G.J. Breedveld, B.A. Oostra, G. Pezzoli, V.
Bonifati, The G6055A (G2019S) mutation in LRRK2 is frequent in both
early and late onset Parkinson’s disease and originates from a common
ancestor, J. Med. Genet. 42 (2005) e65.
[15] S. Goldwurm, M. Zini, A. Di Fonzo, D. De Gaspari, C. Siri, E.J. Simons,
M. van Doeselaar, S. Tesei, A. Antonini, M. Canesi, A. Zecchinelli, C. Mar-
iani, N. Meucci, G. Sacilotto, R. Cilia, I.U. Isaias, A. Bonetti, F. Sironi,
S. Ricca, B.A. Oostra, V. Bonifati, G. Pezzoli, LRRK2 G2019S mutation
and Parkinson’s disease: a clinical, neuropsychological and neuropsychi-
atric study in a large Italian sample, Parkinsonism and Related Disorders,
Parkinsonism Relat. Disord. 12 (2006) 410–419.
[16] S. Goldwurm, M. Zini, L. Mariani, S. Tesei, R. Miceli, F. Sironi, M.
Clementi, V. Bonifati, G. Pezzoli, Evaluation of LRRK2 G2019S pene-
trance: relevance of genetic counseling in Parkinson disease, Neurology
14 (2007) 1141–1143.
[17] E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, a.
Kaganovich, M.P. van der Brug, A. Beilina, J. Blackinton, K.J. Thomas, R.
Ahmad, D.W. Miller, S. Kesavapany, A. Singleton, A. Lees, R.J. Harvey,
K. Harvey, M.R. Cookson, Kinase activity is required for the toxic effects
of mutant LRRK2/dardarin, Neurobiol. Dis. 23 (2006) 329–341.
[18] A.J. Hughes, Y. Ben-Shlomo, S.E. Daniel, A.J. Lees, What features improve
the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopatho-
logic study, 1992, Neurology 57 (2001) S34–S38.
[19] J. Infante, E. Rodriguez, O. Combarros, I. Mateo, A. Fontalba, J. Pascual,
A. Oterino, J.M. Polo, C. Leno, J. Berciano, LRRK2 G2019S is a common
mutation in Spanish patients with late-onset Parkinson’s disease, Neurosci.
Lett. 395 (2006) 224–226.
[20] J. Kachergus, I.F. Mata, M. Hulihan, J.P. Taylor, S. Lincoln, J. Aasly,
J.M. Gibson, O.A. Ross, T. Lynch, J. Wiley, H. Payami, J. Nutt, D.M.
Maraganore, K. Czyzewski, M. Styczynska, Z.K. Wszolek, M.J. Farrer,
M. Toft, Identification of a novel LRRK2 mutation linked to autosomal
dominant parkinsonism: evidence of a common founder across European
populations, Am. J. Hum. Genet. 76 (2005) 672–680.
[21] D.M. Kay, C.P. Zabetian, S.A. Factor, J.G. Nutt, A. Samii, A. Griffith, T.D.
Bird, P. Kramer, D.S. Higgins, H. Payami, Parkinson’s disease and LRRK2:
frequency of a common mutation in U.S. movement disorder clinics, Mov.
Disord. 21 (2006) 319–323.
[22] T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S.
Minoshima, M. Yokochi, Y. Mizuno, N. Shimizu, Mutations in the parkin
gene cause autosomal recessive juvenile parkinsonism, Nature 392 (1998)
605–608.
[23] S. Lesage, P. Ibanez, E. Lohmann, P. Pollak, F. Tison, M. Tazir, A.L.
Leutenegger, J. Guimaraes, A.M. Bonnet, Y. Agid, A. Durr, A. Brice,
French Parkinson’s Disease Genetics Study Group, G2019S LRRK2 muta-
tion in French and North African families with Parkinson’s disease, Ann.
Neurol. 58 (2005) 784–787.
[24] S. Lesage, A. Durr, M. Tazir, E. Lohmann, A.L. Leutenegger, S. Janin,
P. Pollak, A. Brice, LRRK2 G2019S as a cause of Parkinson’s disease in
North African Arabs, N. Engl. J. Med. 354 (2006) 422–423.
[25] I. Litvan, K.P. Bhatia, D.J. Burn, C.G. Goetz, A.E. Lang, I. McKeith, N.
Quinn, K.D. Sethi, C. Shults, G.K. Wenning, Movement Disorders Society
Scientific Issues Committee. Movement Disorders Society Scientific Issues
Committee report: SIC Task Force appraisal of clinical diagnostic criteria
for Parkinsonian disorders, Mov. Disord. 18 (2003) 467–486.
[26] I.F. Mata, J.M. Kachergus, J.P. Taylor, S. Lincoln, J. Aasly, T. Lynch, M.M.
Hulihan, S.A. Cobb, R.M. Wu, C.S. Lu, C. Lahoz, Z.K. Wszolek, M.J. Far-
rer, Lrrk2 pathogenic substitutions in Parkinson’s disease, Neurogenetics
6 (2005) 171–177.
[27] I.F. Mata, J.P. Taylor, J. Kachergus, H. Hulihan, C. Huerta, C. Lahoz,
M. Blazquez, L.M. Guisasola, C. Salvador, R. Ribacoba, C. Martinez, M.
Farrer, V. Alvarez, LRRK2 R1441G in Spanish patients with Parkinson’s
disease, Neurosci. Lett. 382 (2005) 309–311.